Oncology Drugs

Major academic centers no longer hold a monopoly on medical breakthroughs. A look at how community networks are democratizing cutting-edge cancer research.

Sweeping data from EHA 2026 shows Syndax's Revuforj achieving remarkable success across leukemia settings, signaling a new standard of care and a major market coup.

A $4M grant for a Parkinson's drug isn't just charity; it's a strategic bet on a new era of medicine, where philanthropy acts as the catalyst for the next big cure.

New data on an all-oral combo therapy for AML shows remarkable efficacy, offering new hope for patients and cementing Syndax's competitive advantage.

A key clinical trial completion in Japan signals a major shift in prostate cancer care, heralding the arrival of advanced PSMA-targeted theranostics.

Hainan's new medical tourism hub is more than a hospital—it's a strategic play for global dominance, using exclusive drugs and VIP service to lure patients.

Aethlon Medical is advancing a device to filter pathogens from the bloodstream, viewing it as a firewall for the body's internal communication network.

MAIA Biotechnology isn't just opening a new trial site; it's accelerating its assault on a $70B market with a drug showing remarkable early results.

A market set to triple, driven by gene-level therapies, promises a revolution for children with rare epilepsies. But can our systems deliver this hope?

At EHA 2026, Parexel isn't just presenting data; it's unveiling a bold new strategy to fix a broken system and accelerate life-saving blood cancer drugs.

One in six people globally faces infertility, yet a pervasive stigma silences their struggle. A worldwide movement is now uniting millions to demand change.

A new partnership between software specialist Cosylab and hardware innovator Heron aims to overcome the final hurdles in deploying a promising cancer therapy worldwide.

Health Canada's Priority Review for a new Duchenne muscular dystrophy drug signals hope for patients and a strategic test of Canada's rare disease market.

As new drugs outpace manufacturing capacity, a French giant bets on local production in China to build the supply chains of tomorrow's therapies.

A groundbreaking partnership between Servier and n-Lorem Foundation blends pharma R&D muscle with non-profit agility to develop ASO therapies for the rarest of diseases.

Sanofi's promising nerve disease drug fails in late-stage trials, leaving vulnerable patients in limbo and highlighting the brutal realities of medical innovation.

Mickey Mikitani shifts to Executive Chairman, installing a new CEO to navigate the high-stakes journey from visionary science to U.S. market reality.

Takeda seeks FDA approval for its gut-focused drug ENTYVIO in children, a major step toward a new era of treatment for the rising tide of pediatric IBD.

Facing burnout and fearing for patient safety, 250 clinicians at Seattle's top cancer centers are unionizing, challenging the very structure of modern healthcare.

A novel TYK2 inhibitor that can enter the central nervous system has begun human trials, signaling a new frontier for treating diseases like MS and lupus.